Moreover, CD8+, as well as CD4+ T cells transduced with the TCR for NPM1-mutated peptide, demonstrated efficient specific lysis by Cr51-release assay of NPM1-mutated, but not NPM1 wild-type, HLA-A2-restricted primary leukemic blasts, indicating that CLAVEEVSL is a neoantigen that can be efficiently targeted on AML cells by NPM1-mutated sequence TCR gene transfer in a CD8 coreceptor-independent fashion. The gene discussed is CD8A; the disease is acute myeloid leukemia.